Washington-based synthetic biology platform AbSci has collaborated with Massachusetts-based biotechnology company EQRx to jointly discover and develop novel drugs across multiple therapeutic areas, including oncology and immunology.
The partnership will focus on developing novel protein-based therapeutics by leveraging AbSci’s AI-based drug creation technology and EQRx’s clinical development and commercial expertise.
The terms and financial details of the collaboration have not been disclosed. However, AbSci has the option of making further investments in progressive stages of the drug development process in exchange for an increased share of product sales proceeds.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.